HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coniff, R. F. Search for Related Content PubMed PubMed Citation Articles by Coniff, R. F.

Ann Thorac Surg 1998;65:S31-S34
© 1998 The Society of Thoracic Surgeons

The Bayer 022 Compassionate-Use Pediatric Study

^a Bayer Corporation, West Haven, Connecticut, USA

Address reprint requests to Dr Christopher Mojcik, Bayer Corporation, 400 Morgan Ln, West Haven, CT 06516

Presented at Risk Assessment of Major Perioperative Issues in Pediatric Cardiac Surgery, Washington, DC, May 7, 1997.

Background. As part of a compassionate-use study, a placebo-controlled study was undertaken to assess the efficacy of aprotinin in patients undergoing any procedure associated with cardiopulmonary bypass and at increased risk of perioperative bleeding. This article reviews results in 116 patients 16 years of age or less.

Methods. Patients were randomly assigned to four treatment groups: high dose, low dose, pump prime only, and placebo. Efficacy was measured by four parameters: requirement for units of donor blood, requirement for units of donor blood and blood product, thoracic drainage volumes, and rates of reoperation required primarily because of diffuse bleeding. Results were separately analyzed in all patients, patients undergoing primary procedures, patients undergoing repeat procedures, neonates and infants 1 year of age or less, and patients older than 1 year of age.

Results. There was a trend toward reduced blood and blood product requirements with aprotinin use, least evident in neonates and infants and particularly evident in patients undergoing repeat procedures. Aprotinin did not reduce drainage volumes in this pediatric population.

Conclusions. There is a trend toward benefit with aprotinin use in a pediatric population, as measured by requirement for blood and blood product, in patients who are more than 1 year of age and in patients undergoing a repeat operation rather than a primary sternotomy operation.

This article has been cited by other articles:

				D. M. Arnold, D. A. Fergusson, A. K.C. Chan, R. J. Cook, G. A. Fraser, W. Lim, M. A. Blajchman, and D. J. Cook Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. Anesth. Analg., March 1, 2006; 102(3): 731 - 737. [Abstract] [Full Text] [PDF]

				L. A. Gramlich and S. D. Barnes Aprotinin Use in Pediatric Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2001; 5(1): 117 - 121. [Abstract] [PDF]